We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis (AMBINEB)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00391014
First Posted: October 23, 2006
Last Update Posted: May 12, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
PETHEMA Foundation
  Purpose
The trial is planned as a multicentric, national, phase II, open-label trial to evaluate safety and tolerance of nebulized Liposomal Amphotericin B (Ambisome) for LMA patients during the induction therapy ,intensification, plus Allogeneic Haematopoietic Progenitor Cell transplant in due course, as well for patients diagnosed of several malignant haematologic diseases and treated with Allogeneic Haematopoietic Progenitor Cell Transplant

Condition Intervention Phase
Acute Myeloid Leukemia Allogeneic Haematopoietic Progenitor Cell Transplant Drug: liposomal Amphotericine B Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: AMBINEB: Clinical Trial to Evaluate Tolerance and Safety of Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis in Patients With Acute Myeloid Leukemia and Allogeneic Haematopoietic Progenitor Cell Transplant (Alo-HPCT)

Resource links provided by NLM:


Further study details as provided by PETHEMA Foundation:

Primary Outcome Measures:
  • Efficacy and safety prophylaxis against IPA in LMA patients. [ Time Frame: 1 year ]

Estimated Enrollment: 150
Study Start Date: January 2006
Study Completion Date: April 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1

AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.

If patient required ALO-TPH, the prophylaxis should be followed.

Drug: liposomal Amphotericine B

AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.

If patient required ALO-TPH, the prophylaxis should be followed.


Detailed Description:

The invasive fungal infection (IFI) is the most common cause of mortality related to autologous stem cell transplant. Taking into account that Saprophytic Aspergillus is usually acquired by inhalation, to protect the bronchial tree just before the tissue invasion is quite attractive. In haematologic patients, as well as those ones subjected to an Allogeneic haematopoietic progenitor cell transplant, there is another group of patients at high risk of Invasive Pulmonary Aspergillosis (IPA). These are those patients with acute myeloid leucemia (AML), submitted to induction, intensification or consolidation polychemotherapy. The IPA incidence rate in these patients, whenever during their evolution, reaches 18-20%, with usual treatments. Furthermore, unlike allogeneic haematopoietic progenitor cell transplant patients, neutropenia was the only IPA risk factor. Nowadays, pharmacologic prophylaxis against IPA, in patients with allogeneic haematopoietic progenitor cell transplant and patients affected by AML in induction or intensification therapy is far from being optimal, because of problems related to tolerance and drug interactions .

The Nebulized Liposomal Amphotericin B (Ambisome) prophylaxis against IPA has shown good tolerance, safety and efficacy in lung transplant recipients.

Extrapolating the results obtained in lung transplant recipients, we get the conclusion that it would be essential to study safety and tolerance of nebulized AMBISOME in the group of patients with different peculiarities, mucositis secondary to chemotherapy, and high incidence of IPA in order to reach the goal of evaluate its efficacy as prophylaxis against IPA in this kind of patients

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient has decided voluntary to consent his or her participation signing the consent form before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
  • Patients with Acute myeloid Leukemia (AML), that will start induction chemotherapy or those patients submitted to an Allogeneic haematopoietic progenitor cell transplant.
  • The patient is >18 years old.

Exclusion Criteria:

  • Patient with prior Invasive Pulmonary Aspergillosis (IPA) history.
  • History of allergy or hypersensitivity to Amphotericin B.
  • Patient with intellectual deficit or patients with psychological alterations that make impossible the trial understanding.
  • Pregnancy or breastfeeding.
  • Patient has received other investigational drug or non traded product within 30 days before trial beginning.
  • Patient is enrolled in another clinical research study or/and is receiving an investigational agent for any reason.
  • Patient had major surgery within 4 weeks before enrollment.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00391014


Locations
Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario de la Princesa
Madrid, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Hospital Universitario la Fe
Valencia, Spain
Sponsors and Collaborators
PETHEMA Foundation
Investigators
Principal Investigator: Ruiz Isabel, Dr Hospital Vall d'Hebron
Principal Investigator: Rovira Montserrat, Dr Hospital Clinic of Barcelona
  More Information

Additional Information:
Publications:

Responsible Party: Pethema, pethema
ClinicalTrials.gov Identifier: NCT00391014     History of Changes
Other Study ID Numbers: 2005-000703-34
AMBINEB
First Submitted: October 20, 2006
First Posted: October 23, 2006
Last Update Posted: May 12, 2009
Last Verified: May 2009

Keywords provided by PETHEMA Foundation:
Acute myeloid Leukemia
Allogeneic haematopoietic progenitor cell transplant
Acute Invasive Aspergillosis

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Aspergillosis
Pulmonary Aspergillosis
Invasive Pulmonary Aspergillosis
Neoplasms by Histologic Type
Neoplasms
Mycoses
Hyalohyphomycosis
Dermatomycoses
Lung Diseases, Fungal
Skin Diseases, Infectious
Skin Diseases
Lung Diseases
Respiratory Tract Diseases
Invasive Fungal Infections
Amphotericin B
Liposomal amphotericin B
Amebicides
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Anti-Bacterial Agents
Antifungal Agents